Anokion’s autoimmunity platform evolution
Why Anokion shifted its focus to a platform that delivers tolerance-inducing antigens directly to the liver
When the science suggested the liver, and not the blood, could be the better target tissue for tolerance-inducing autoantigens, Anokion devised a platform around the former. About 18 months after its pivot, the company is poised to bring its first therapy into the clinic before the end of the year, with another one to follow within 12 months.
In the last week, Anokion S.A. closed a $40 million series B round and presented preclinical data for one of its lead programs at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Stockholm. Versant Ventures, Novartis Venture Fund, Novo Ventures, Celgene Corp. (NASDAQ:CELG) and select Swiss-based private investors participated in the B round (see “Anokion Puts Liver to the Test”)...